Journal article

Efficacy and Safety of Lu-177-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study

Andrei Gafita, Wolfgang P Fendler, Wang Hui, Shahneen Sandhu, Manuel Weber, Rouzbeh Esfandiari, Jeremie Calais, Isabel Rauscher, Hendrik Rathke, Robert Tauber, Ebrahim S Delpassand, Wolfgang A Weber, Ken Herrmann, Johannes Czernin, Matthias Eiber, Michael S Hofman

European Urology | ELSEVIER | Published : 2020


The 177Lu-labeled prostate-specific membrane antigen (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer is under investigation in a phase III trial (VISION: NCT03511664). However, patients with diffuse bone involvement, diagnosed with a "superscan" by bone scintigraphy at baseline, were excluded due to a lack of efficacy and safety data. We therefore aimed to investigate the feasibility of LuPSMA in patients with diffuse bone marrow involvement on baseline PSMA-targeted positron emission tomography. The primary end points were prostate-specific antigen (PSA) response (Prostate Cancer Working Group 3 [PCWG3]), hematologic safety profile (Common Terminology Crite..

View full abstract


Funding Acknowledgements

Michael S. Hofman thanks Peter MacCallum Foundation for providing a Clinical Fellowship supporting the research, the Australian Nuclear Science and Technology Organisation (ANSTO, Sydney, Australia) for supplying Lutetium-177 (no carrier added), and Advanced Biochemical Compounds (ABX, Radeberg, Germany), subsequently purchased by Endocyte (a Novartis company) for supply of PSMA-617.